News
SNY
47.03
-4.51%
-2.22
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Seeking Alpha · 5h ago
Sanofi Shares Fall After CEO Change -- Update
The Wall Street Journal · 11h ago
Sanofi Names Belén Garijo as New CEO, Effective After April Shareholder Meeting
TipRanks · 12h ago
LIVE MARKETS-Money managers' AI-driven selloff overdone, says Morgan Stanley
Reuters · 13h ago
Rollins Posts Downbeat Results, Joins Paycom Software, Cisco, Applovin And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 14h ago
Sanofi (SNYNF) Receives a Hold from Barclays
TipRanks · 14h ago
LIVE MARKETS-Share repurchases to provide renewed support for Europe
Reuters · 15h ago
Sanofi downgraded to Neutral from Buy at BofA
TipRanks · 15h ago
Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'
Benzinga · 15h ago
Sanofi ‘decides not to renew’ mandate of CEO Paul Hudson
TipRanks · 15h ago
Sanofi says Belen Garijo to succeed Paul Hudson as CEO
TipRanks · 15h ago
Sanofi CEO Paul Hudson To Depart; Belén Garijo Named Successor
NASDAQ · 19h ago
Sanofi names Belén Garijo as CEO
Seeking Alpha · 20h ago
Looking for Dividends? Consider Europe.
Barron‘s · 20h ago
Belén Garijo Named CEO of Sanofi
Reuters · 20h ago
PRESS RELEASE: BELÉN GARIJO TO BECOME CHIEF EXECUTIVE OFFICER OF SANOFI
Reuters · 20h ago
ESIH, XSDR, HLTH: These ETFs Provide Exposure to Europe’s Top Healthcare Companies
TipRanks · 1d ago
Sanofi Breaks Above 200-Day Moving Average - Bullish for SNY
NASDAQ · 1d ago
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review
Benzinga · 1d ago
Sanofi Reports 1.22 Billion Issued Shares and 1.35 Billion Voting Rights as of January 2026
Reuters · 1d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.